Document:

Amended and Restated Secured Convertible Mimimum Borrowing Note.

 Exhibit 10.70 
  
 THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR ANY STATE SECURITIES LAWS. THIS NOTE AND THE COMMON SHARES ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID
ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ACCENTIA BIOPHARMACEUTICALS, INC. THAT SUCH REGISTRATION IS NOT REQUIRED. 
  
 AMENDED AND RESTATED 
 SECURED CONVERTIBLE MINIMUM BORROWING NOTE 
  
 FOR VALUE RECEIVED, each of ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation (the “Parent”), and the other companies listed on Exhibit A attached hereto (such other companies together
with the Parent, each a “Company” and collectively, the “Companies”), jointly and severally, promises to pay to LAURUS MASTER FUND, LTD., c/o M&C Corporate Services Limited, P.O. Box 309 GT, Ugland House, South
Church Street, George Town, Grand Cayman, Cayman Islands, Fax: 345-949-8080 (the “Holder”) or its registered assigns or successors in interest, the sum of Two Million Five Hundred Thousand Dollars ($2,500,000), or, if different, the
aggregate principal amount of all Loans (as defined in the Security Agreement referred to below), together with any accrued and unpaid interest hereon, on April 29, 2006 (the “Maturity Date”) if not sooner indefeasibly paid in full;
provided, however, if the Parent shall have consummated the initial public offering of Common Stock (as defined in the Security Agreement) on or prior to March 31, 2006, the Maturity Date shall be April 29, 2008. 
  
 Capitalized terms used herein without definition shall have the meanings
ascribed to such terms in the Security Agreement among the Companies and the Holder dated as of the date hereof (as amended, modified and/or supplemented from time to time, the “Security Agreement”). 
  
 The following terms shall apply to this Amended and Restated Secured
Convertible Minimum Borrowing Note (this “Note”): 
  
 ARTICLE I 
 CONTRACT RATE 
  
 1.1 Contract Rate. Subject to Sections 4.2 and 5.10, interest payable on the outstanding principal amount of this Note (the “Principal
Amount”) shall accrue at a rate per annum equal to the “prime rate” published in The Wall Street Journal from time to time (the “Prime Rate”), plus two percent (2.0%) (the “Contract Rate”).
The Contract Rate shall be increased or decreased as the case may be for each increase or decrease in the Prime Rate in an amount equal to such increase or decrease in the Prime Rate; each change to be effective as of the day of the change in the
Prime Rate. Subject to Section 1.2, the Contract Rate shall not at any time be less than seven and three-quarters percent (7.75%). Interest shall be (i) calculated 

 on the basis of a 360 day year, and (ii) payable monthly, in arrears, commencing on May 4, 2005 on the first business day
of each consecutive calendar month thereafter through and including the Maturity Date and on the Maturity Date, whether by acceleration or otherwise. 
  
 1.2 Contract Rate Adjustments and Payments. The Contract Rate shall be calculated on the last business day of each calendar month hereafter (other
than for increases or decreases in the Prime Rate which shall be calculated and become effective in accordance with the terms of Section 1.1) until the Maturity Date (each a “Determination Date”) and shall be subject to adjustment
as set forth herein. If (i) the Parent shall have registered the shares of the Common Stock underlying the conversion of each Minimum Borrowing Note and each Warrant on a registration statement declared effective by the Securities and Exchange
Commission (the “SEC”), and (ii) the market price (the “Market Price”) of the Common Stock as reported by Bloomberg, L.P. on the Principal Market for the five (5) trading days immediately preceding a Determination
Date exceeds the then applicable Fixed Conversion Price by at least twenty-five percent (25%), the Contract Rate for the succeeding calendar month shall automatically be reduced by 200 basis points (200 b.p.) (2%) for each incremental twenty-five
percent (25%) increase in the Market Price of the Common Stock above the then applicable Fixed Conversion Price. Notwithstanding the foregoing (and anything to the contrary contained herein), in no event shall the Contract Rate at any time be less
than zero percent (0%). 
  
 ARTICLE II 
 LOANS; PAYMENTS UNDER THIS NOTE 
  
 2.1 Loans. All Loans evidenced by this Note shall be made in accordance with the terms and provisions of the Security Agreement. 
  
 2.2 No Effective Registration. Notwithstanding anything to the
contrary herein, the Holder shall not be required to accept shares of Common Stock as payment following a conversion by the Holder if there fails to exist an effective current Registration Statement (as defined in the Registration Rights Agreement)
covering the shares of Common Stock to be issued, or if an Event of Default hereunder exists and is continuing, unless such requirement is otherwise waived in writing by the Holder in whole or in part at the Holder’s option. 
  
 2.3 Optional Redemption in Cash. The Companies will have the option of
prepaying this Note (“Optional Redemption”) by paying to the Holder a sum of money equal to one hundred thirty percent (130%) of the principal amount of this Note together with accrued but unpaid interest thereon and any and all
other sums due, accrued or payable to the Holder arising under this Note, the Security Agreement, or any other Ancillary Agreement (the “Redemption Amount”) outstanding on the Redemption Payment Date (as defined below). The Company
shall deliver to the Holder a written notice of redemption (the “Notice of Redemption”) specifying the date for such Optional Redemption (the “Redemption Payment Date”), which date shall be seven (7) days after the
date of the Notice of Redemption (the “Redemption Period”). A Notice of Redemption shall not be effective with respect to any portion of this Note for which the Holder has previously delivered a Notice of Conversion (defined below)
pursuant to Section 3.1, or for conversions elected to be made by the Holder pursuant to Section 3.1 during the Redemption Period. The Redemption Amount shall be determined as if such Holder’s conversion elections had been completed immediately
prior to the date of the Notice of 
  

 2 

 
Redemption. On the Redemption Payment Date, the Redemption Amount (plus any additional interest and fees accruing on the Notes during the Redemption Period)
must be irrevocably paid in full in immediately available funds to the Holder. In the event the Companies fail to pay the Redemption Amount on the Redemption Payment Date, then such Redemption Notice shall be null and void. 
  
 ARTICLE III 
 CONVERSION RIGHTS AND FIXED CONVERSION PRICE 
  
 3.1 Optional Conversion. Subject to the terms of this Article III, the Holder shall have the right, but not the obligation, at any time until the
Maturity Date, or during an Event of Default (as defined in Article IV), and, subject to the limitations set forth in Section 3.2 hereof, to convert all or any portion of the outstanding Principal Amount and/or accrued interest and fees due and
payable into fully paid and nonassessable shares of the Common Stock at the Fixed Conversion Price. For purposes hereof, subject to Section 3.6 hereof, the initial “Fixed Conversion Price” shall be $3.30; provided
that, on the date of consummation of the initial public offering of Common Stock, the “Fixed Conversion Price” shall be adjusted to an amount equal to 85% of the issuance price of the Common Stock issued in connection with such
initial public offering of Common Stock (the “IPO Price”). The shares of Common Stock to be issued upon such conversion are herein referred to as the “Conversion Shares.” 
  
 3.2 Conversion Limitation. Notwithstanding anything contained herein
to the contrary, the Holder shall not be entitled to convert pursuant to the terms of this Note an amount that would be convertible into that number of Conversion Shares which would exceed the difference between (i) 4.99% of the outstanding shares
of Common Stock and (ii) the number of shares of Common Stock beneficially owned by the Holder. For purposes of the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Exchange Act and
Regulation 13d-3 thereunder. The Conversion Shares limitation described in this Section 3.2 shall automatically become null and void without any notice to any Company upon the occurrence and during the continuance of an Event of Default, or upon 75
days prior notice to the Parent. Notwithstanding anything contained herein to the contrary, the provisions of this Section 3.2 are irrevocable and may not be waived by the Holder or any Company. 
  
 3.3 Mechanics of Holder’s Conversion. In the event that the
Holder elects to convert this Note into Common Stock, the Holder shall give notice of such election by delivering an executed and completed notice of conversion in substantially the form of Exhibit A hereto (appropriately completed) (“Notice
of Conversion”) to the Parent and such Notice of Conversion shall provide a breakdown in reasonable detail of the Principal Amount, accrued interest and fees that are being converted. On each Conversion Date (as hereinafter defined) and in
accordance with its Notice of Conversion, the Holder shall make the appropriate reduction to the Principal Amount, accrued interest and fees as entered in its records and shall provide written notice thereof to the Parent within two (2) Business
Days after the Conversion Date. Each date on which a Notice of Conversion is delivered or telecopied to the Parent in accordance with the provisions hereof shall be deemed a Conversion Date (the “Conversion Date”). Pursuant to the
terms of the Notice of Conversion, the Parent will issue instructions to the transfer agent accompanied by an opinion of counsel within one (1) Business Day of the date of the delivery to 
  

 3 

 the Parent of the Notice of Conversion and shall cause the transfer agent to transmit the certificates representing the
Conversion Shares to the Holder by crediting the account of the Holder’s designated broker with the Depository Trust Corporation (“DTC”) through its Deposit Withdrawal Agent Commission (“DWAC”) system within
three (3) Business Days after receipt by the Parent of the Notice of Conversion (the “Delivery Date”). In the case of the exercise of the conversion rights set forth herein the conversion privilege shall be deemed to have been
exercised and the Conversion Shares issuable upon such conversion shall be deemed to have been issued upon the date of receipt by the Parent of the Notice of Conversion. The Holder shall be treated for all purposes as the record holder of the
Conversion Shares, unless the Holder provides the Parent written instructions to the contrary. 
  
 3.4 Late Payments. Each Company understands that a delay in the delivery of the Conversion Shares in the form required pursuant to this Article beyond the Delivery Date could result in economic loss to the
Holder. As compensation to the Holder for such loss, in addition to all other rights and remedies which the Holder may have under this Note, applicable law or otherwise, the Companies shall, jointly and severally, pay late payments to the Holder for
any late issuance of Conversion Shares in the form required pursuant to this Article III upon conversion of this Note, in the amount equal to $500 per Business Day after the Delivery Date. The Companies shall, jointly and severally, make any
payments incurred under this Section in immediately available funds upon demand. 
  
 3.5 Conversion Mechanics. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing that portion of the principal and interest and fees to be converted,
if any, by the then applicable Fixed Conversion Price. 
  
 3.6
Adjustment Provisions. The Fixed Conversion Price and number and kind of shares or other securities to be issued upon conversion determined pursuant to Section 3.1 shall be subject to adjustment from time to time upon the occurrence of
certain events during the period that this conversion right remains outstanding, as follows: 
  
 (a) Reclassification. If the Parent at any time shall, by reclassification or otherwise, change the Common Stock into the same or a different number of securities of any class or classes, this Note, as to the
unpaid Principal Amount and accrued interest thereon, shall thereafter be deemed to evidence the right to purchase an adjusted number of such securities and kind of securities as would have been issuable as the result of such change with respect to
the Common Stock (i) immediately prior to or (ii) immediately after such reclassification or other change at the sole election of the Holder. 
  
 (b) Stock Splits, Combinations and Dividends. If the shares of Common Stock are subdivided or combined into a greater or smaller number of shares
of Common Stock, or if a dividend is paid on the Common Stock or any preferred stock issued by the Parent in shares of Common Stock, the Fixed Conversion Price shall be proportionately reduced in case of subdivision of shares or stock dividend or
proportionately increased in the case of combination of shares, in each such case by the ratio which the total number of shares of Common Stock outstanding immediately after such event bears to the total number of shares of Common Stock outstanding
immediately prior to such event. 
  

 4 

 (c) Share Issuances. Subject to the provisions of this Section 3.6, if the Parent shall at any
time prior to the conversion or repayment in full of the Principal Amount issue any shares of Common Stock or securities convertible into Common Stock to a person other than the Holder (except (i) pursuant to Sections 3.6(a) or (b) above; (ii)
pursuant to options, warrants, or other obligations to issue shares outstanding on the date hereof as disclosed to the Holder in writing; or (iii) pursuant to options that may be issued under any employee incentive stock option and/or any qualified
stock option plan adopted by the Parent) for a consideration per share (the “Offer Price”) less than the Fixed Conversion Price in effect at the time of such issuance, then the Fixed Conversion Price shall be immediately reset to
such lower Offer Price. For purposes hereof, the issuance of any security of the Parent convertible into or exercisable or exchangeable for Common Stock shall result in an adjustment to the Fixed Conversion Price upon the issuance of such
securities. 
  
 (d) Computation of Consideration. For
purposes of any computation respecting consideration received pursuant to Section 3.6(c) above, in the case of the issuance of shares of Common Stock for cash, the consideration shall be the amount of such cash. 
  
 3.7 Reservation of Shares. During the period the conversion right
exists, the Parent will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of Conversion Shares upon the full conversion of this Note and the warrant. The Parent represents that upon
issuance, the Conversion Shares will be duly and validly issued, fully paid and non-assessable. The Parent agrees that its issuance of this Note shall constitute full authority to its officers, agents, and transfer agents who are charged with the
duty of executing and issuing stock certificates to execute and issue the necessary certificates for the Conversion Shares upon the conversion of this Note. 
  
 3.8 Registration Rights. The Holder has been granted registration rights with respect to the Conversion Shares as set forth in a Registration
Rights Agreement. 
  
 3.9 Issuance of New Note. Upon any
partial conversion of this Note, a new Note containing the same date and provisions of this Note shall, at the request of the Holder, be issued by the Parent to the Holder for the principal balance of this Note and interest which shall not have been
converted or paid. Subject to the provisions of Article IV of this Note, the Parent shall not pay any costs, fees or any other consideration to the Holder for the production and issuance of a new Note. 
  
 3.10 Further Conversion Limitation. Notwithstanding anything contained
herein to the contrary, the Holder shall not be entitled to convert pursuant to the terms of this Note any amounts that would be convertible into Conversion Shares prior to the earlier to occur of (i) two hundred seventy (270) days after the date
hereof and (i) one hundred eighty (180) days after the date of the initial public offering of Common Stock. The Conversion Shares limitation described in this Section 3.10 shall automatically become null and void without any notice to any Company
upon the occurrence and during the continuance of an Event of Default. 
  
 3.11 Additional Conversion. If the Company shall have registered the shares of the Common Stock underlying the conversion of this Note and each Warrant on a registration statement declared effective by the SEC, then, if (i) the
average closing price of the Common 
  

 5 

 Stock as reported by Bloomberg, L.P. on the Principal Market for five consecutive (5) trading days (the
“Determination Date”) shall be greater than or equal to 125% of the IPO Price, then the Holder shall convert into Common Stock an amount equal to twenty per cent (20%) of the average dollar trading volume for the consecutive five
trading days immediately preceding the Determination Date (the “Maximum Amount”). Notwithstanding the immediately foregoing, the Maximum Amount shall not exceed twenty percent (20%) of the aggregate dollar trading volume of the
Common Stock for the period of twenty (20) trading days immediately preceding the Determination Date (the “Aggregate Maximum Amount”). In determining the Maximum Amount, any Maximum Amount conversion required hereunder shall be
aggregated with all Maximum Amount conversions required under this Note and the Secured Convertible Term Note between the Holder and the Company; in no event shall the Holder convert, pursuant to this Section 3.11 any amount in excess of the
Aggregate Maximum Amount. Conversions made pursuant to this Section 3.11 shall be deemed to be effective on the Determination Date. No more than one Determination Date may occur during any consecutive five (5) trading day period, and no more than
two (2) Determination Dates may occur in any calendar month. Any principal amount of this Note that is converted pursuant to this Section 3.11 shall be deemed to constitute payments of outstanding principal. 
  
 ARTICLE IV 
 EVENTS OF DEFAULT AND DEFAULT RELATED PROVISIONS 
  
 4.1 Events of Default. The occurrence of an Event of Default under the Security Agreement shall constitute an event of default (“Event of
Default”) hereunder. 
  
 4.2 Default Interest.
Following the occurrence and during the continuance of an Event of Default, the Companies shall, jointly and severally, pay additional interest on the outstanding principal balance of this Note in an amount equal to one and one half percent (1.5%)
per month, and all outstanding Obligations, including unpaid interest, shall continue to accrue interest at such additional interest rate from the date of such Event of Default until the date such Event of Default is cured or waived. 
  
 4.3 Default Payment. Following the occurrence and during the
continuance of an Event of Default, the Holder, at its option, may elect, in addition to all rights and remedies of the Holder under the Security Agreement and the Ancillary Agreements and all obligations of each Company under the Security Agreement
and the Ancillary Agreements, to require the Companies, jointly and severally, to make a Default Payment (“Default Payment”). The Default Payment shall be 130% of the outstanding principal amount of the Note, plus accrued but unpaid
interest, all other fees then remaining unpaid, and all other amounts payable hereunder. The Default Payment shall be applied first to any fees due and payable to the Holder pursuant to the Notes and/or the Ancillary Agreements, then to accrued and
unpaid interest due on the Notes, the Security Agreement and then to the outstanding principal balance of the Notes. The Default Payment shall be due and payable immediately on the date that the Holder has exercised its rights pursuant to this
Section 4.3. 
  

 6 

 ARTICLE V 
 MISCELLANEOUS 
  
 5.1
Conversion Privileges. The conversion privileges set forth in Article III shall remain in full force and effect immediately from the date hereof until the date this Note is indefeasibly paid in full and irrevocably terminated. 
  
 5.2 Cumulative Remedies. The remedies under this Note shall be
cumulative. 
  
 5.3 Failure or Indulgence Not Waiver. No
failure or delay on the part of the Holder hereof in the exercise of any power, right or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. All rights and remedies existing hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available. 
  
 5.4 Notices. Any notice herein required or permitted to be given shall be in writing and shall be deemed effectively
given: (a) upon personal delivery to the party notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by registered
or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the
respective Company at the addresses provided for such Company in the Security Agreement executed in connection herewith, and to the Holder at the address provided in the Security Agreement for such Holder, with a copy to John E. Tucker, Esq., 825
Third Avenue, 14th Floor, New York, New York 10022, facsimile number (212) 541-4434, or at such other address as the
respective Company or the Holder may designate by ten days advance written notice to the other parties hereto. 
  
 5.5 Amendment Provision. The term “Note” and all references thereto, as used throughout this instrument, shall mean this instrument as
originally executed, or if later amended or supplemented, then as so amended or supplemented, and any successor instrument as such successor instrument may be amended or supplemented. 
  
 5.6 Assignability. This Note shall be binding upon each Company and its successors and assigns, and shall inure to
the benefit of the Holder and its successors and assigns, and may be assigned by the Holder in accordance with the requirements of the Security Agreement. No Company may assign any of its obligations under this Note without the prior written consent
of the Holder, any such purported assignment without such consent being null and void. 
  
 5.7 Cost of Collection. In case of any Event of Default under this Note, the Companies shall, jointly and severally, pay the the Holder’s reasonable costs of collection, including reasonable
attorneys’ fees. 
  
 5.8 Governing Law, Jurisdiction and
Waiver of Jury Trial. 
  
 (a) THIS NOTE SHALL BE GOVERNED BY
AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. 
  

 7 

 (b) EACH COMPANY HEREBY CONSENTS AND AGREES THAT THE STATE OR FEDERAL COURTS LOCATED IN THE COUNTY OF
NEW YORK, STATE OF NEW YORK SHALL HAVE EXCLUSIVE JURISDICTION TO HEAR AND DETERMINE ANY CLAIMS OR DISPUTES BETWEEN ANY COMPANY, ON THE ONE HAND, AND THE HOLDER, ON THE OTHER HAND, PERTAINING TO THIS NOTE, THE SECURITY AGREEMENT OR ANY OF THE OTHER
ANCILLARY AGREEMENTS OR TO ANY MATTER ARISING OUT OF OR RELATED TO THIS NOTE, THE SECURITY AGREEMENT OR ANY OF THE OTHER ANCILLARY AGREEMENTS; PROVIDED, THAT EACH COMPANY ACKNOWLEDGES THAT ANY APPEALS FROM THOSE COURTS MAY HAVE TO BE HEARD BY
A COURT LOCATED OUTSIDE OF THE COUNTY OF NEW YORK, STATE OF NEW YORK; AND FURTHER PROVIDED, THAT NOTHING IN THIS NOTE SHALL BE DEEMED OR OPERATE TO PRECLUDE THE HOLDER FROM BRINGING SUIT OR TAKING OTHER LEGAL ACTION IN ANY OTHER
JURISDICTION TO COLLECT THE OBLIGATIONS, TO REALIZE ON THE COLLATERAL OR ANY OTHER SECURITY FOR THE OBLIGATIONS, OR TO ENFORCE A JUDGMENT OR OTHER COURT ORDER IN FAVOR OF THE HOLDER. EACH COMPANY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH
JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND EACH COMPANY HEREBY WAIVES ANY OBJECTION WHICH IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON CONVENIENS. EACH COMPANY HEREBY WAIVES
PERSONAL SERVICE OF THE SUMMONS, COMPLAINT AND OTHER PROCESS ISSUED IN ANY SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINT AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE COMPANY AT THE ADDRESS
SET FORTH IN THE SECURITY AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER OF THE COMPANY’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAILS, PROPER POSTAGE PREPAID. 
  
 (c) EACH COMPANY DESIRES THAT ITS DISPUTES BE RESOLVED BY A JUDGE APPLYING
SUCH APPLICABLE LAWS. THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF THE JUDICIAL SYSTEM AND OF ARBITRATION, EACH COMPANY HERETO WAIVES ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION, SUIT, OR PROCEEDING BROUGHT TO RESOLVE ANY DISPUTE,
WHETHER ARISING IN CONTRACT, TORT, OR OTHERWISE BETWEEN THE HOLDER, AND/OR ANY COMPANY ARISING OUT OF, CONNECTED WITH, RELATED OR INCIDENTAL TO THE RELATIONSHIP ESTABLISHED BETWEEN THEM IN CONNECTION WITH THIS NOTE, THE SECURITY AGREEMENT, ANY OTHER
ANCILLARY AGREEMENT OR THE TRANSACTIONS RELATED HERETO OR THERETO. 
  
 5.9 Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and
shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Note. 
  

 8 

 5.10 Maximum Payments. Nothing contained herein shall be deemed to establish or require the
payment of a rate of interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder exceed the maximum rate permitted by such law, any payments in
excess of such maximum rate shall be credited against amounts owed by the Companies to the Holder and thus refunded to the Companies. 
  
 5.11 Security Interest and Guarantee. The Holder has been granted a security interest in (i) certain assets of the Companies as more fully
described in the Security Agreement and the Master Security Agreement, (ii) the equity interests of certain Subsidiaries of the Parent pursuant to the Stock Pledge Agreement dated as of the date hereof and (iii) the equity interests of Star
Scientific, Inc. held by The Francis E. O’Donnell, Jr. Irrevocable Trust No. 1pursuant to the O’Donnell Stock Pledge Agreement dated as of the date hereof. The obligations of the Companies under this Note are guaranteed by certain
Subsidiaries of the Parent pursuant to the Subsidiaries Guaranty dated as of the date hereof. 
  
 5.12 Construction. Each party acknowledges that its legal counsel participated in the preparation of this Note and, therefore, stipulates that the rule of construction that ambiguities are to be resolved
against the drafting party shall not be applied in the interpretation of this Note to favor any party against the other. 
  
 5.13 Amendment and Restatement. This Note amends and restates in its entirety and is given in substitution for but not in satisfaction of that
certain $2,500,000 Secured Convertible Minimum Borrowing Note dated as of April 29, 2005 executed by Accentia Biopharmaceuticals, Inc. and The Analytica Group, Inc. in favor of the Holder. 
  
 [Balance of page intentionally left blank; signature page follows] 

 

 9 

 IN WITNESS WHEREOF, each Company has caused this Amended and Restated Secured Convertible Minimum
Borrowing Note to be signed in its name effective as of the 29th day of April 2005. 
  

			
	 ACCENTIA BIOPHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ Francis E. O’Donnell, Jr.

	 	 	 Name: Franchise E. O’Donnell, Jr.
 Title: Chief Executive Officer

  

	
	WITNESS:
	
	  
	 

  

			
	 THE ANALYTICA GROUP, INC.

		
	 By:
	 	 /s/ Steve Arikian

	 	 	 Name: Stephen Arikian
 Title: Chief Executive Officer

  

	
	WITNESS:
	
	  
	 

  

			
	 LAURUS MASTER FUND, LTD.

		
	 By:
	 	 /s/ Eugene Grin

	 	 	 Name: Eugene Grin
 Title: Director

  

 10 

 EXHIBIT A 
  
 OTHER COMPANIES 
  
 The Analytica Group, Inc. 
  
  

 11 

 EXHIBIT B 
  
 NOTICE OF CONVERSION 
  

(To be executed by the Holder in order to convert the 
 Amended and Restated Secured Convertible Minimum Borrowing Note) 
  
 The undersigned hereby elects to convert $             of the principal and
$             of the interest due on the Amended and Restated Secured Convertible Minimum Borrowing Note dated as of April 29, 2005 (the “Note”) issued by Accentia
Biopharmaceuticals, Inc. (the “Parent”) and the other Companies named and as defined therein into shares of Common Stock of the Parent in accordance with the terms and conditions set forth in the Note, as of the date written below.

  
  

			
	 Date of Conversion:
	  	_______________________________________________________________________
		
	Conversion Price:	  	_______________________________________________________________________
		
	Shares To Be Delivered:	  	_______________________________________________________________________
		
	Signature:	  	_______________________________________________________________________
		
	Print Name:	  	_______________________________________________________________________
		
	Address:	  	_______________________________________________________________________
		
	 Holder DWAC instructions
	  	_______________________________________________________________________

  

 12Registration Rights Agreement

 EXHIBIT 10.75 
  
 REGISTRATION RIGHTS AGREEMENT 
  

This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 29, 2005, by and between Accentia
Biopharmaceuticals, Inc., a Florida corporation (the “Company”), and Laurus Master Fund, Ltd. (the “Purchaser”). 
  
 This Agreement is made pursuant to (i) the Securities Purchase Agreement, dated as of the date hereof, by and between the Purchaser and the Company (as
amended, modified and/or supplemented from time to time, the “Securities Purchase Agreement”), and pursuant to the Note and the Warrants referred to therein and (ii) the Security Agreement, dated as of the date hereof, by and among the
Purchaser, the Company and various subsidiaries of the Company (as amended, modified or supplemented from time to time, the “Security Agreement”), and pursuant to the Notes and the Warrants referred to therein. 
  
 The Company and the Purchaser hereby agree as follows: 
  
 1. Definitions. Capitalized terms used and not otherwise defined
herein that are defined in the Securities Purchase Agreement or the Security Agreement, as applicable, shall have the meanings given such terms in the Securities Purchase Agreement or the Security Agreement, as applicable. As used in this Agreement,
the following terms shall have the following meanings: 
  
 “Commission” means the Securities and Exchange Commission. 
  
 “Common Stock” means shares of the Company’s common stock, par value $0.001 per share. 
  
 “Effectiveness Date” means, (i) with respect to the initial Registration Statement required to be filed in connection with the Note (as
defined in the Securities Purchase Agreement) issued on the initial funding date under the Securities Purchase Agreement and the Minimum Borrowing Note (as defined in the Security Agreement) issued on the initial funding date under the Security
Agreement and the Warrants issued on such initial funding date, a date no later than the earlier to occur of (x) two hundred seventy (270) days following the date hereof and (y) one hundred twenty (180) days following the date of the Initial Public
Offering and (ii) with respect to each additional Registration Statement required to be filed hereunder, a date no later than thirty (30) days following the applicable Filing Date. 
  
 “Effectiveness Period” has the meaning set forth in Section 2(a). 
  
 “Exchange Act” means the Securities Exchange Act of 1934, as
amended, and any successor statute. 
  
 “Filing
Date” means, with respect to (1) the initial Registration Statement which is required to be filed in connection with the shares of Common Stock issuable upon (A) conversion of the Note issued on the initial funding date, (B) the Minimum
Borrowing Note issued on the initial funding date and (C) exercise of a Warrant issued on the intial funding date, a date no later than the earlier to occur of (x) two hundred ten (210) days after the date hereof 

 
and (y) ninety (90) days following the date of the Initial Public Offering, (2) the Registration Statement required to be filed in connection with each
additional Minimum Borrowing Note funded after the initial funding date, the date which is thirty (30) days after such funding of such additional Minimum Borrowing Note, but in no event earlier than ninety (90) days following the date of the initial
public offering of Common Stock, (3) the Registration Statement required to be filed in connection with the shares of Common Stock issuable to the Holder upon exercise of a Warrant issued after the intial funding date, the date which is thirty (30)
days after the issuance of such Warrant, but in no event earlier than ninety (90) days following the date of the initial public offering of Common Stock, and (4) the Registration Statement required to be filed in connection with the shares of Common
Stock issuable to the Holder as a result of adjustments to the Fixed Conversion Price or the Exercise Price, as the case may be, made pursuant to Section 3.5 of the Note, Section 2.5 of the Revolving Note, Section 3.5 of the Minimum Borrowing Notes,
Section 4 of the Warrant or otherwise, thirty (30) days after the occurrence of such event or the date of the adjustment of the Fixed Conversion Price or Exercise Price, as the case may be, but in no event earlier than ninety (90) days following the
date of the initial public offering of Common Stock. 
  
 “Holder” or “Holders” means the Purchaser or any of its affiliates or transferees to the extent any of them hold Registrable Securities, other then those purchasing Registrable Securities in a market
transaction. 
  
 “Indemnified Party” has the
meaning set forth in Section 5(c). 
  
 “Indemnifying
Party” has the meaning set forth in Section 5(c). 
  
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
  
 “Prospectus” means the prospectus included in a Registration
Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as
amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement, and all other amendments and supplements to the Prospectus,
including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
  
 “Registrable Securities” means the shares of Common Stock issued upon the conversion of the Note (as defined in each of the Securities
Purchase Agreement), the Minimum Borrowing Note (as defined in the Security Agreement) and issuable upon exercise of the Warrants. 
  
 “Registration Statement” means each registration statement required to be filed hereunder, including the Prospectus therein, amendments
and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in such registration statement.

  

 2 

 “Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act,
as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
  
 “Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 
  
 “Securities Act” means the Securities Act of 1933, as amended, and any successor statute. 
  
 “Security Agreement” has the meaning given to such term in
the Preamble hereto. 
  
 “Trading Market” means
any of the NASD Over The Counter Bulletin Board, NASDAQ SmallCap Market, the NASDAQ National Market, the American Stock Exchange or the New York Stock Exchange 
  

“Warrants” means the Common Stock purchase warrants issued in connection with the Securities Purchase Agreement and/or the Security
Agreement, whether on the date thereof or thereafter. 
  
 2.
Registration. 
  
 (a) On or prior to each Filing Date, the
Company shall prepare and file with the Commission a Registration Statement covering the Registrable Securities for a selling stockholder resale offering to be made on a continuous basis pursuant to Rule 415. Each Registration Statement shall be on
Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith). The Company shall (i) with respect to
the Registration Statement required to be filed in connection with the Note issued on the initial funding date under the Securities Purchase Agreement, the Minimum Borrowing Note issued on the initial funding date under the Security Agreement and
the Warrants issued on such initial funding date, use its best efforts to cause such Registration Statement to become effective as provided herein; provided that, such Registration Statement shall be required to remain effective as
provided herein notwithstanding the use of best efforts by the Company and (ii) in respect of each other Registration Statement, cause each such Registration Statement to become effective and remain effective as provided herein notwithstanding the
use of best efforts by the Company. The Company shall use its reasonable commercial efforts to cause each Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event no
later than the Effectiveness Date. The Company shall use its reasonable commercial efforts to keep each Registration Statement continuously effective under the Securities Act until the date which is the earlier date of when (i) all Registrable
Securities covered by such Registration Statement have been sold or (ii) all Registrable Securities covered by such Registration Statement may be sold immediately without registration under the Securities Act and without volume restrictions pursuant
to Rule 144(k), as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent and the affected Holders (each, an “Effectiveness Period”).

  

 3 

 If: (i) any Registration Statement is not filed on or prior to the applicable Filing Date for such
Registration Statement; (ii) a Registration Statement filed hereunder is not declared effective by the Commission by the applicable Effectiveness Date; (iii) after a Registration Statement is filed with and declared effective by the Commission, a
Discontinuation Event (as hereafter defined) shall occur and be continuing, or such Registration Statement ceases to be effective (by suspension or otherwise) as to all Registrable Securities to which it is required to relate at any time prior to
the expiration of the Effectiveness Period applicable to such Registration Statement (without being succeeded immediately by an additional Registration Statement filed and declared effective), for a period of time which shall exceed 30 days in the
aggregate per year or more than 20 consecutive calendar days (defined as a period of 365 days commencing on the date such Registration Statement is declared effective); or (iv) the Common Stock is not listed or quoted, or is suspended from trading
on any Trading Market for a period of three (3) consecutive Trading Days (provided the Company shall not have been able to cure such trading suspension within 30 days of the notice thereof or list the Common Stock on another Trading Market); (any
such failure or breach being referred to as an “Event,” and for purposes of clause (i) or (ii) the date on which such Event occurs, or for purposes of clause (iii) the date which such 30 day or 20 consecutive day period (as the case may
be) is exceeded, or for purposes of clause (iv) the date on which such three (3) Trading Day period is exceeded, being referred to as “Event Date”), then as partial relief for the damages to the Purchaser by reason of the occurrence of any
such Event (which remedy shall not be exclusive of any other remedies available at law or in equity), the Company shall pay to the Purchaser for each day that an Event has occurred and is continuing, an amount in cash equal to one-thirtieth
(1/30th) of the product of: (A) the sum of (I) the original principal amount of the Note (as defined in the
Securities Purchase Agreement) plus (II) the then outstanding principal amount of the Minimum Borrowing Note (as defined in the Security Agreement) multiplied by (B) 0.02. While such Event continues, such liquidated damages shall be paid not
less often than each thirty (30) days. Any unpaid liquidated damages as of the date when an Event has been cured by the Company shall be paid within three (3) days following the date on which such Event has been cured by the Company. In the event
the Company fails to make any payments pursuant to this Section 2(b) in a timely manner, such payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. 
  
 (b) Within three business days of the Effectiveness Date, the Company shall
cause its counsel to issue a blanket opinion in the form attached hereto as Exhibit A, to the transfer agent stating that the shares are subject to an effective registration statement and can be reissued free of restrictive legend upon notice of a
sale by the Purchaser and confirmation by the Purchaser that it has complied with the prospectus delivery requirements, provided that the Company has not advised the transfer agent orally or in writing that the opinion has been withdrawn. Copies of
the blanket opinion required by this Section 2(c) shall be delivered to the Purchaser within the time frame set forth above. 
  

 4 

 3. Registration Procedures. If and whenever the Company is required by the provisions hereof to
effect the registration of any Registrable Securities under the Securities Act, the Company will, as expeditiously as possible: 
  
 (a) prepare and file with the Commission a Registration Statement with respect to such Registrable Securities, respond as promptly as possible to any
comments received from the Commission, and use its best efforts to cause such Registration Statement to become and remain effective for the Effectiveness Period with respect thereto, and promptly provide to the Purchaser copies of all filings and
Commission letters of comment relating thereto; 
  
 (b) prepare
and file with the Commission such amendments and supplements to such Registration Statement and the Prospectus used in connection therewith as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of
all Registrable Securities covered by such Registration Statement and to keep such Registration Statement effective until the expiration of the Effectiveness Period applicable to such Registration Statement; 
  
 (c) furnish to the Purchaser such number of copies of the Registration
Statement and the Prospectus included therein (including each preliminary Prospectus) as the Purchaser reasonably may request to facilitate the public sale or disposition of the Registrable Securities covered by such Registration Statement;

  
 (d) use its commercially reasonable efforts to register or
qualify the Purchaser’s Registrable Securities covered by such Registration Statement under the securities or “blue sky” laws of such jurisdictions within the United States as the Purchaser may reasonably request, provided, however,
that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where it is not so qualified or to consent to general service of process in any such jurisdiction;

  
 (e) list the Registrable Securities covered by such
Registration Statement with any securities exchange on which the Common Stock of the Company is then listed; 
  
 (f) immediately notify the Purchaser at any time when a Prospectus relating thereto is required to be delivered under the Securities Act, of the happening
of any event of which the Company has knowledge as a result of which the Prospectus contained in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated
therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and 
  
 (g) make available for inspection by the Purchaser and any attorney, accountant or other agent retained by the Purchaser, all publicly available,
non-confidential financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s officers, directors and employees to supply all publicly available, non-confidential information reasonably
requested by the attorney, accountant or agent of the Purchaser. 
  
 4. Registration Expenses. All expenses relating to the Company’s compliance with Sections 2 and 3 hereof, including, without limitation, all registration and filing fees, printing 

  

 5 

 
expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including reasonable counsel fees)
incurred in connection with complying with state securities or “blue sky” laws, fees of the NASD, transfer taxes, fees of transfer agents and registrars, fees of, and disbursements incurred by, one counsel for the Holders are called
“Registration Expenses”. All selling commissions applicable to the sale of Registrable Securities, including any fees and disbursements of any special counsel to the Holders beyond those included in Registration Expenses, are called
“Selling Expenses.” The Company shall only be responsible for all Registration Expenses. 
  
 5. Indemnification. 
  
 (a) In the event of a registration of any Registrable Securities under the Securities Act pursuant to this Agreement, the Company will indemnify and hold
harmless each Holder, and its officers, directors and each other person, if any, who controls such Holder within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such Holder, or such
persons may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material
fact contained in any Registration Statement under which such Registrable Securities were registered under the Securities Act pursuant to this Agreement, any preliminary Prospectus or final Prospectus contained therein, or any amendment or
supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse such Holder, and
each such person for any reasonable legal or other expenses incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by or on
behalf of the Purchaser or any such person in writing specifically for use in any such document. 
  
 (b) In the event of a registration of the Registrable Securities under the Securities Act pursuant to this Agreement, the Purchaser will indemnify and
hold harmless the Company, and its officers, directors and each other person, if any, who controls the Company within the meaning of the Securities Act, against all losses, claims, damages or liabilities, joint or several, to which the Company or
such persons may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any
material fact which was furnished in writing by the Purchaser to the Company expressly for use in (and such information is contained in) the Registration Statement under which such Registrable Securities were registered under the Securities Act
pursuant to this Agreement, any preliminary Prospectus or final Prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and each such person for any reasonable legal or other expenses incurred by them in connection with investigating or defending any such loss,
claim, damage, liability or action, provided, however, that the Purchaser will be liable in any such case if and 

  

 6 

 
only to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission
or alleged omission so made in conformity with information furnished in writing to the Company by or on behalf of the Purchaser specifically for use in any such document. Notwithstanding the provisions of this paragraph, the Purchaser shall not be
required to indemnify any person or entity in excess of the amount of the aggregate net proceeds received by the Purchaser in respect of Registrable Securities in connection with any such registration under the Securities Act. 
  
 (c) Promptly after receipt by a party entitled to claim indemnification
hereunder (an “Indemnified Party”) of notice of the commencement of any action, such Indemnified Party shall, if a claim for indemnification in respect thereof is to be made against a party hereto obligated to indemnify such Indemnified
Party (an “Indemnifying Party”), notify the Indemnifying Party in writing thereof, but the omission so to notify the Indemnifying Party shall not relieve it from any liability which it may have to such Indemnified Party other than under
this Section 5(c) and shall only relieve it from any liability which it may have to such Indemnified Party under this Section 5(c) if and to the extent the Indemnifying Party is prejudiced by such omission. In case any such action shall be brought
against any Indemnified Party and it shall notify the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with
counsel satisfactory to such Indemnified Party, and, after notice from the Indemnifying Party to such Indemnified Party of its election so to assume and undertake the defense thereof, the Indemnifying Party shall not be liable to such Indemnified
Party under this Section 5(c) for any legal expenses subsequently incurred by such Indemnified Party in connection with the defense thereof; if the Indemnified Party retains its own counsel, then the Indemnified Party shall pay all fees, costs and
expenses of such counsel, provided, however, that, if the defendants in any such action include both the Indemnified Party and the Indemnifying Party and the Indemnified Party shall have reasonably concluded that there may be
reasonable defenses available to it which are different from or additional to those available to the Indemnifying Party or if the interests of the Indemnified Party reasonably may be deemed to conflict with the interests of the Indemnifying Party,
the Indemnified Party shall have the right to select one separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the reasonable expenses and fees of such separate counsel and other expenses
related to such participation to be reimbursed by the Indemnifying Party as incurred. 
  
 (d) In order to provide for just and equitable contribution in the event of joint liability under the Securities Act in any case in which either (i) the Purchaser, or any officer, director or controlling person of the
Purchaser, makes a claim for indemnification pursuant to this Section 5 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last
right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 5 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of the
Purchaser or such officer, director or controlling person of the Purchaser in circumstances for which indemnification is provided under this Section 5; then, and in each such case, the Company and the Purchaser will contribute to the aggregate
losses, claims, damages or liabilities to which they may be subject (after contribution from others) in such proportion so that the Purchaser is responsible only for the portion represented by the percentage that the public offering price of its
securities offered by the Registration Statement 

  

 7 

 
bears to the public offering price of all securities offered by such Registration Statement, provided, however, that, in any such case, (A) the
Purchaser will not be required to contribute any amount in excess of the public offering price of all such securities offered by it pursuant to such Registration Statement; and (B) no person or entity guilty of fraudulent misrepresentation (within
the meaning of Section 10(f) of the Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. 
  
 6. Representations and Warranties. 
  
 (a) Upon consummation of the Initial Public Offering, the Common Stock shall be registered pursuant to Section 12(b) or 12(g) of the Exchange Act and,
except with respect to certain matters which the Company has disclosed to the Purchaser on Schedule 12(u) to the Security Agreement, the Company shall timely filed all proxy statements, reports, schedules, forms, statements and other
documents required to be filed by it under the Exchange Act. The Company has furnished the Purchaser with copies of: (i) its annual audited financial statements for its fiscal year ended September 30, 2004; and (ii) its quarterly unaudited financial
statements for its fiscal quarter ended December 31, 2004 (collectively, the “Financial Statements”). Each Financial Statement was, at the time of its filing, in substantial compliance with the requirements of its respective form
and none of the Financial Statements (and the notes thereto), as of their respective filing dates, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading. The Financial Statements comply as to form in all material respects with applicable accounting requirements and the published rules and regulations of the
Commission or other applicable rules and regulations with respect thereto. Such Financial Statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods
involved (except (i) as may be otherwise indicated in such Financial Statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed) and fairly present in all
material respects the financial condition, the results of operations and the cash flows of the Company and its subsidiaries, on a consolidated basis, as of, and for, the periods presented in each such Financial Statement. 
  
 (b) The Company has prepared in all material respects the listing application
in respect of its Common Stock to be, upon consummation of the Initial Public Offering, listed on the NASDAQ National Market and the Company reasonably believes that it and such listing application shall satisfy all requirements for such listing on
the NASDAQ National Market, and once listed on the NASDAQ National Market, the Company shall do all things necessary for the continuation of such listing. The Company has not received any notice that its Common Stock will not be listed on the NASDAQ
National Market upon consummation of the Initial Public Offering or that its Common Stock shall not meet all requirements for such listing. 
  
 (c) Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of
any security or solicited any offers to buy any security (other than an offering to the Holder under the Securities Purchase Agreement) under circumstances that would cause the offering of the Securities pursuant to the Security Agreement to be
integrated with prior offerings by the Company for purposes of the 

  

 8 

 
Securities Act which would prevent the Company from selling the Common Stock pursuant to Rule 506 under the Securities Act, or any applicable
exchange-related stockholder approval provisions, nor will the Company or any of its affiliates or subsidiaries take any action or steps that would cause the offering of the Common Stock to be integrated with other offerings (other than such
concurrent offering to the Purchaser). 
  
 (d) The Warrants, the
Notes and the shares of Common Stock which the Purchaser may acquire pursuant to the Warrants and the Notes are all restricted securities under the Securities Act as of the date of this Agreement. The Company will not issue any stop transfer order
or other order impeding the sale and delivery of any of the Registrable Securities at such time as such Registrable Securities are registered for public sale or an exemption from registration is available, except as required by federal or state
securities laws. 
  
 (e) The Company understands the nature of the
Registrable Securities issuable upon the conversion of each Note and the exercise of each Warrant and recognizes that the issuance of such Registrable Securities may have a potential dilutive effect. The Company specifically acknowledges that its
obligation to issue the Registrable Securities is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership interests of other shareholders of the Company. 
  
 (f) Except for agreements made in the ordinary course of business, there is
no agreement that has not been filed with the Commission as an exhibit to a registration statement or to a form required to be filed by the Company under the Exchange Act, the breach of which could reasonably be expected to have a Material Adverse
Effect or would prohibit or otherwise interfere with the ability of the Company to enter into this Agreement in any material respect. 
  
 (g) The Company will at all times have authorized and reserved a sufficient number of shares of Common Stock for the full conversion of each Note and
exercise of the Warrants. 
  
 7. Miscellaneous. 

 
 (a) Remedies. In the event of a breach by the Company or by a
Holder, of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be
entitled to specific performance of its rights under this Agreement. 
  
 (b) No Piggyback on Registrations. Except as and to the extent set forth on Schedule 7(b) hereto, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities of
the Company in any Registration Statement other than the Registrable Securities, and the Company shall not after the date hereof enter into any agreement providing any such right for inclusion of shares in the Registration Statement to any of its
security holders. Except as and to the extent specified in Schedule 7(b) hereto, the Company has not previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been
fully satisfied. 
  

 9 

 (c) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery
requirements of the Securities Act as applicable to it in connection with sales of Registrable Securities pursuant to any Registration Statement. 
  
 (d) Discontinued Disposition. Each Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a notice from the Company
of the occurrence of a Discontinuation Event (as defined below), such Holder will forthwith discontinue disposition of such Registrable Securities under the applicable Registration Statement until such Holder’s receipt of the copies of the
supplemented Prospectus and/or amended Registration Statement or until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus may be resumed, and, in either case, has received copies of any
additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company may provide appropriate stop orders to enforce the provisions of this paragraph. For
purposes of this Section 7(d), a “Discontinuation Event” shall mean (i) when the Commission notifies the Company whether there will be a “review” of such Registration Statement and whenever the Commission comments in writing on
such Registration Statement (the Company shall provide true and complete copies thereof and all written responses thereto to each of the Holders); (ii) any request by the Commission or any other Federal or state governmental authority for amendments
or supplements to such Registration Statement or Prospectus or for additional information; (iii) the issuance by the Commission of any stop order suspending the effectiveness of such Registration Statement covering any or all of the Registrable
Securities or the initiation of any Proceedings for that purpose; (iv) the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale
in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and/or (v) the occurrence of any event or passage of time that makes the financial statements included in such Registration Statement ineligible for inclusion
therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement,
Prospectus or other documents so that, in the case of such Registration Statement or Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 
  
 (e) Amendments and Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and the Holders of the then outstanding Registrable Securities. Notwithstanding the
foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of certain Holders and that does not directly or indirectly affect the rights of other Holders may be given by
Holders of at least a majority of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the
provisions of the immediately preceding sentence. 
  

 10 

 (f) Notices. Any notice or request hereunder may be given to the Company or the Purchaser at the
respective addresses set forth below or as may hereafter be specified in a notice designated as a change of address under this Section 7(g). Any notice or request hereunder shall be given by registered or certified mail, return receipt requested,
hand delivery, overnight mail, Federal Express or other national overnight next day carrier (collectively, “Courier”) or telecopy (confirmed by mail). Notices and requests shall be, in the case of those by hand delivery, deemed to have
been given when delivered to any party to whom it is addressed, in the case of those by mail or overnight mail, deemed to have been given three (3) business days after the date when deposited in the mail or with the overnight mail carrier, in the
case of a Courier, the next business day following timely delivery of the package with the Courier, and, in the case of a telecopy, when confirmed. The address for such notices and communications shall be as follows: 
  

			
	 If to the Company:
	  	Accentia Biopharmaceuticals, Inc.
	 	  	324 South Hyde Park Ave., Suite 350
	 	  	Tampa, Florida 33606
	 	  	 Attention:      Chief Financial Officer

	 	  	 Facsimile:      813-258-1659

		
	 with a copy to:
	  	Alan Pearce fax 941-308-4400 and Sam Duffey 941-918-2841
		
	 If to a Purchaser:
	  	To the address set forth under such Purchaser name on the signature pages hereto.
		
	 If to any other Person who is
	  	 
	 then the registered Holder:
	  	To the address of such Holder as it appears in the stock transfer books of the Company

  
 or such other address as may be
designated in writing hereafter in accordance with this Section 7(g) by such Person. 
  
 (g) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The
Company may not assign its rights or obligations hereunder without the prior written consent of each Holder. Each Holder may assign their respective rights hereunder in the manner and to the Persons as permitted under the Notes and the Securities
Purchase Agreement. 
  
 (h) Execution and Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same agreement. In the event that any signature is delivered
by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original
thereof. 
  

 11 

 (i) Governing Law, Jurisdiction and Waiver of Jury Trial. THIS AGREEMENT SHALL BE GOVERNED BY AND
CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. The Company hereby consents and agrees that the state or federal
courts located in the County of New York, State of New York shall have exclusion jurisdiction to hear and determine any Proceeding between the Company, on the one hand, and the Purchaser, on the other hand, pertaining to this Agreement or to any
matter arising out of or related to this Agreement; provided, that the Purchaser and the Company acknowledge that any appeals from those courts may have to be heard by a court located outside of the County of New York, State of New York, and
further provided, that nothing in this Agreement shall be deemed or operate to preclude the Purchaser from bringing a Proceeding in any other jurisdiction to collect the obligations, to realize on the Collateral or any other security
for the obligations, or to enforce a judgment or other court order in favor of the Purchaser. The Company expressly submits and consents in advance to such jurisdiction in any Proceeding commenced in any such court, and the Company hereby waives any
objection which it may have based upon lack of personal jurisdiction, improper venue or forum non conveniens. The Company hereby waives personal service of the summons, complaint and other process issued in any such Proceeding and agrees that
service of such summons, complaint and other process may be made by registered or certified mail addressed to the Company at the address set forth in Section 7(g) and that service so made shall be deemed completed upon the earlier of the
Company’s actual receipt thereof or three (3) days after deposit in the U.S. mails, proper postage prepaid. The parties hereto desire that their disputes be resolved by a judge applying such applicable laws. Therefore, to achieve the best
combination of the benefits of the judicial system and of arbitration, the parties hereto waive all rights to trial by jury in any Proceeding brought to resolve any dispute, whether arising in contract, tort, or otherwise between the Purchaser
and/or the Company arising out of, connected with, related or incidental to the relationship established between then in connection with this Agreement. If either party hereto shall commence a Proceeding to enforce any provisions of this Agreement,
the Securities Purchase Agreement, any Related Agreement, the Security Agreement or any other Ancillary Agreement, then the prevailing party in such Proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other
costs and expenses incurred with the investigation, preparation and prosecution of such Proceeding. 
  
 (j) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. 
  
 (k) Severability. If any term, provision, covenant or restriction of
this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way
be affected, impaired or invalidated, and the parties hereto shall use their reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or
restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid,
illegal, void or unenforceable. 
  

 12 

 (l) Headings. The headings in this Agreement are for convenience of reference only and shall not
limit or otherwise affect the meaning hereof. 
  
 [Balance of page
intentionally left blank; signature page follows] 
  

 13 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first
written above. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Francis E. O’ Donnell, Jr.

	 Name:
	 	 Francis E. O’ Donnell, Jr.

	 Title:
	 	 CEO

	
	LAURUS MASTER FUND, LTD.
		
	 By:
	 	 /s/ Eugene Grin

	 Name:
	 	 Eugene Grin

	 Title:
	 	 Director

	
	 Address for Notices:

	
	 825 Third Avenue, 14th Floor

	 New York, New York 10022

	 Attention: John Tucker, Esq.

	 Facsimile: 212-541-4434

  

 14 

 EXHIBIT A 
  

                    ,
200     
  
 Wachovia Equity Services 
 1525 West W.T. Harris Blvd. (3C3) 
 Charlotte, North Carolina 28288

 Attn:
                                     
 Tel: (800) 829-8432 
  

	 	Re:	Accentia Biopharmaceuticals, Inc. Registration Statement on Form [S-3] 

  

Ladies and Gentlemen: 
  
 As in-house counsel to Accentia Biopharmaceuticals, Inc., a Florida corporation (the “Company”), I have been requested to render my opinion to
you in connection with the resale by the individuals or entities listed on Schedule A attached hereto (the “Selling Stockholders”), of an aggregate of             
shares (the “Shares”) of the Company’s Common Stock. 
  
 A Registration Statement on Form [S-3] under the Securities Act of 1933, as amended (the “Act”), with respect to the resale of the Shares was declared effective by the Securities and Exchange Commission on [date]. Enclosed is the
Prospectus dated [date]. I understand that the Shares are to be offered and sold in the manner described in the Prospectus. 
  
 Based upon the foregoing, upon request by the Selling Stockholders at any time while the registration statement remains effective, it is my opinion that
the Shares have been registered for resale under the Act and new certificates evidencing the Shares upon their transfer or re-registration by the Selling Stockholders may be issued without restrictive legend. I will advise you if the registration
statement is not available or effective at any point in the future. 
  
 Very truly yours, 
  
 [Company counsel] 

 Schedule A to Exhibit A 
  

					
	 Selling Stockholder

	  	 R/N/O

	  	 Shares Being Offered

 SCHEDULE 7(b) 

 LAURUS MASTER FUND, LTD. 
  
 June 9, 2005 
 Accentia
Biopharmaceuticals, Inc. 
 324 South Hyde Park Ave Suite 350 
 Tampa, FL 33606 
  
 Gentlemen, 
  
 Reference is hereby made to that certain Registration Rights Agreement
entered into as of April 29, 2005, between Laurus Master Fund, Ltd. (“Laurus”) and Accentia Biopharmaceuticals, Inc. (“Accentia”) (the “Registration Rights Agreement”). All capitalized terms used in this letter and not
otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement: 
  
 Per our discussions, this letter will confirm your interpretation that: 
  
 (a) pursuant to terms of the Registration Rights Agreement, if Accentia does not file a Registration Statement on or before
the applicable Filing Date or the applicable Registration Statement is not declared effective by the SEC by the applicable Effectiveness Date, subject to the qualification described in clause (b) below, an event of default under the Note or the
Registration Rights Agreement will not arise as a direct result thereof; and 
  
 (b) the only payment, penalty or liquidated damage imposed upon Accentia as a result of the failure by Accentia to file a Registration Statement on or before the applicable Filing Date and/or the failure by Accentia
to cause a Registration Statement to be declared effective by the SEC on or before the applicable Effectiveness Date, shall be the liquidated damages as calculated in accordance with Section 2(a) of the Registration Rights Agreement and payable in
cash; for the avoidance of doubt, for each day that any failure by Accentia to file a Registration Statement and/or cause a Registration Statement to be declared effective, in each case within the time frames alluded to above, continues without
remedy, such liquidated damages shall accrue at a rate per day equal to one-thirtieth (1/30th) of the product of: (A) the sum of (I) the original principal amount of the Note (as defined in the Securities Purchase Agreement) plus (II) the then
outstanding principal amount of the Minimum Borrowing Note (as defined in the Security Agreement) multiplied by (B) 0.02. Such liquidated damages shall accrue and become payable pursuant to the terms and conditions of Section 2(a) of the
Registration Rights Agreement and, to the extent Accentia fails to pay to Laurus such liquidated damages when they become so due (or within the applicable grace period related thereto), an Event of Default may arise under the Note. In the event that
there exists on any day before a failure by Accentia to file a Registration Statement on or before the applicable Filing Date and the failure by Accentia to cause a Registration Statement to be declared effective by the SEC on or before the
applicable Effectiveness Date, “double” liquidated damages shall not accrue as a result thereof and shall only accrue on a basis consistent with the calculation set forth in the second preceding sentence of this clause (b). 
  
 Furthermore, the definition of “Filing Date” set forth in Section 1
of the Registration Rights Agreement is hereby amended by (i) deleting the text “ninety (90)” in each instance appearing therein and (ii) inserting the text “one hundred eighty (180)” in lieu thereof in each case. 

 Other than in respect of the amendment set forth in the immediately preceding sentence, this letter is
intended only to memorialize the mutual interpretation of the provisions of the Registration Rights Agreement noted above and does not otherwise amend, modify or supplement any of the Securities Purchase Agreement or the Related Agreements referred
to therein. 
  
 This letter may not be amended or waived except by
an instrument in writing signed by Accetia and Laurus. This letter may be executed in any number of counterparts, each of which shall be an original and of which, when taken together, shall constitute one agreement. Delivery of an executed signature
page of this letter by facsimile transmission shall be effective as delivery of a manually executed counterpart hereof or thereof, as the case may be. This letter shall be governed by, and construed in accordance with, the laws of the State of New
York. This letter sets forth the entire agreement between the parties hereto as to the matters set forth herein and supersede all prior communications, written or oral, with respect to the matters herein. 
  
  

			
	 Sincerely,
  
 LAURUS MASTER FUND, LTD.

		
	 By:
	 	/S/ EUGENE GRIN
	 Name: Eugene Grin

	 Title: Director

  
 Agreed: 
  
 Accentia Biopharmaceuticals, Inc. 
  

	
	 /s/ James A. McNulty            Its:   Secretary        

 LAURUS MASTER FUND, LTD. 
  

			
	 Accentia Biopharmaceuticals, Inc.
	 	 
	 324 South Hyde Park Ave Suite 350
	 	September 13, 2005
	 Tampa, FL 33606
	 	 

  
 Gentlemen, 

 
 Reference is hereby made to that certain Registration Rights Agreement
entered into as of April 29, 2005, between Laurus Master Fund, Ltd. (“Laurus”) and Accentia Biopharmaceuticals, Inc. (“Accentia”), as amended on June 9, 2005 (as amended, modified or supplemented, the “Registration Rights
Agreement”). All capitalized terms used in this letter and not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement: As a result of the Omnibus Amendment and Consent, dated August 16, 2005,
between Laurus and Accentia, together with the other agreements contemplated thereby, it is necessary to clarify certain matters and terms under the Registration Rights Agreement. The purposes of this letter (this “Amendment”) is to hereby
amend, for retroactive effectiveness as of August 16, 2005, the Registration Rights Agreement as follows: 
  
 (a) Section 1 of the Registration Rights Agreement is hereby amended by inserting the following new definitions therein in appropriate
alphabetical order: 
  
 “Analytica”
shall mean The Analytica Group, Inc., a Florida corporation. 
  
 “Amendment Date” shall have the same meaning ascribed to the term “Amendment Effective Date” in Section 3 of the Omnibus Amendment and Consent, dated as of August 16, 2005 amongst the Company,
Analytica and the Purchaser. 
  
 “Minimum
Borrowing Note” shall mean each Minimum Borrowing Note, issued by the Company and The Analytica Group, Inc. to the Purchaser pursuant to the terms of the Security Agreement, each as amended, modified and/or supplemented from time to time.

  
 “Note” shall mean the Amended and
Restated Secured Convertible Term Note, initially issued by the Company to the Purchaser on April 29, 2005 and amended and restated as of August 16, 2005, in the original principal amount of Ten Million Dollars ($10,000,000), as amended, modified
and/or supplemented from time to time. 
  
 (b)
Section 1 of the Registration Rights Agreement is hereby further amended by deleting the defined terms “Effectiveness Date”, “Filing Date” and “Warrants” apprearing therein and inserting the following new definitions in
lieu thereof in appropriate alphabetical order: 
  
 “‘Effectiveness Date’ means, (i) with respect to the initial Registration Statement required to be filed in connection with the Note issued on the Amendment Date, the Minimum Borrowing Note (as defined in the
Security Agreement) issued on the initial funding date under the Security Agreement and 

 
as amended on the Amendment Date, and the Warrants issued on the Amendment Date, a date no later than the earlier to occur of (x) March 25, 2006 and (y) one
hundred twenty (180) days following the date of the Initial Public Offering and (ii) with respect to each additional Registration Statement required to be filed hereunder, a date no later than thirty (30) days following the applicable Filing
Date.” 
  
 “Filing Date”
means, with respect to (1) the initial Registration Statement which is required to be filed in connection with the shares of Common Stock issuable upon (A) conversion of the Note, (B) conversion of the Minimum Borrowing Note issued on April 29, 2005
and (C) exercise of all Warrants issued on or prior to the Amendment Date, a date no later than January 25, 2006, (2) the Registration Statement required to be filed in connection with each additional Minimum Borrowing Note funded after the
Amendment Date, the date which is thirty (30) days after such funding of such additional Minimum Borrowing Note, but in no event later than the earlier to occur of (x) one hundred eighty (180) days following the date of the Initial Public Offering
of Common Stock and (y) August 1, 2006, (3) the Registration Statement required to be filed in connection with the shares of Common Stock issuable to the Holder upon exercise of a Warrant issued after the Amendment Date, the date which is thirty
(30) days after the issuance of such Warrant, but in no event later than the earlier to occur of (x) one hundred eighty (180) days following the date of the Initial Public Offering of Common Stock and (y) August 1, 2006, and (4) the Registration
Statement required to be filed in connection with the shares of Common Stock issuable to the Holder as a result of adjustments to the Fixed Conversion Price or the Exercise Price, as the case may be, made pursuant to Section 3.5 of the Note, Section
3.5 of the Minimum Borrowing Notes, Section 4 of the Warrants or otherwise, thirty (30) days after the occurrence of such event or the date of the adjustment of the Fixed Conversion Price or Exercise Price, as the case may be, but in no event later
than the earlier to occur of (x) one hundred eighty (180) days following the date of the Initial Public Offering of Common Stock and August 1, 2006.” 
  
 “Warrants” shall mean (i) the Amended and Restated Common Stock Purchase Warrant, issued on April 29, 2005 and amended and
restated as of August 16, 2005, by the Company to the Purchaser, (ii) the Common Stock Purchase Warrant, issued on August 16, 2005 by the Company to the Purchaser and (iii) Common Stock purchase warrants issued in connection with the Securities
Purchase Agreement and/or Security Agreement, after the Amendment Date, each as amended, modified and/or supplemented from time to time. 
  
 (c) Section 2(a) of the Registration Rights Agreement is hereby amended by deleting the third sentence appearing therein and inserting the
following new sentence in lieu thereof: 
  
 “The Company
shall (i) with respect to the Registration Statement required to be filed in connection with the Note, the Minimum Borrowing Note issued on the initial funding date, and the Warrants, use its best efforts to cause such Registration Statement to
become effective as provided herein; provided that, such Registration Statement shall be required to remain effective as provided herein notwithstanding 

 
the use of best efforts by the Company and (ii) in respect of each other Registration Statement, cause each such Registration Statement to become effective
and remain effective as provided herein notwithstanding the use of best efforts by the Company.” 
  
 (d) The amendments set forth above shall be effective with retroactive effect from August 16, 2005 on the date when each of Accentia and
The Analytica Group, Inc. (“Analytica”) and Laurus shall have executed and each of Accentia and Analytica shall have delivered to Laurus its respective counterpart to this Amendment. 
  
 (e) Except as specifically set forth in this Amendment,
there are no other amendments, modifications or waivers to any other document other than the Registration Rights Agreement and each of the Securities Purchase Agreement (as defined in the Registration Rights Agreement), the Related Agreements
referred to in the Securities Purchase Agreement, the Security Agreement (as defined in the Registration Rights Agreement) and the Anciallry Agreements referred to in the Security Agreement remain in full force and effect. 
  
 (f) Each of Accentia and Analytica hereby represents and
warrants to Laurus that (i) no Event of Default exists on the date hereof, after giving effect to this Amendment, (ii) on the date hereof, all representations, warranties and covenants made by each Company in connection with the Loan Documents are
true, correct and complete and (iii) on the date hereof, all of the Company’s and its Subsidiaries’ covenant requirements have been met. 
  
 (g) This Amendment shall be binding upon the parties hereto and their respective successors and permitted assigns and shall inure to the
benefit of and be enforceable by each of the parties hereto and their respective successors and permitted assigns. THIS AMENDMENT SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK. This Amendment may
be executed in any number of counterparts, each of which shall be an original, but all of which shall constitute one instrument. 
  
 IN WITNESS WHEREOF, each of the parties hereto has executed this Amendment or has caused this Amendment to be executed on its behalf by a
representative duly authorized, all as of the date first above set forth. 
  

			
	ACCENTIA BIOPHARMACEUTICALS, INC.
		
	 By:
	 	 /s/ Frank O’Donnell

	 	 	 Name: Frank O’Donnell

	 	 	 Title: Chief Executive Officer

	
	THE ANALYTICA GROUP, INC.
		
	 By:
	 	 /s/ Stephen Arikian

	 	 	 Name: Stephen Arikian

	 	 	 Title: Chief Executive Officer

	
	LAURUS MASTER FUND, LTD.
		
	 By:
	 	 /s/ Eugene Grin

	 	 	 Name: Eugene Grin

	 	 	 Title: Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]